Halo Labs Inc. - CEO, Kiran Sidhu
CEO, Kiran Sidhu
Source: @kiransidhuCEO
  • Halo Labs (NEO:HALO) CEO Kiran Sidhu will present at the Benzinga Cannabis Capital Conference today.
  • The conference will take place at the Fontainebleau Miami Beach Hotel, in Florida.
  • Mr Sidhu will give a presentation on the company’s future growth and pending acquisition in Lesotho, South Africa.
  • Halo’s share price is down 3.33 per cent, with shares currently trading at 14.5 cents apiece.

Cannabis company Halo Labs (HALO) has announced that its CEO Kiran Sidhu will represent Halo at the Benzinga Cannabis Capital Conference today.

The two-day conference is considered to be Miami’s #1 marijuana convention. The event will bring together entrepreneurs, investors, and executives from the booming cannabis industry.

The conference will take place at the Fontainebleau Miami Beach Hotel, in Florida from Monday, February 24thto 25th.

Mr Sidhu will present “Halo Labs: From Oregon Roots to African Growth”, a discussion of the company’s future. In particular, he will discuss Halo’s pending acquisition of the company Bophelo in Lesotho, South Africa. 

A few months ago, Mr Sidhu had the honour of meeting the King and Queen of Lesotho. The royal visit occurred at Bophelo’s cannabis cultivation site in Mafeteng.

The presentation will take place at 3:10pm Eastern Standard Time, on February 24th.

Mr Sidhu will give another presentation the following day, in which he will provide an overview of the company and its future vision. This second presentation will take place at 11:30am Eastern Standard Time, on February 25th.

Halo’s share price is down 3.33 per cent, with shares currently trading at 14.5 cents apiece at 3:17pm EST.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.